Overview

Targeted Polymeric Nanoparticles Loaded With Cetuximab and Decorated With Somatostatin Analogue to Colon Cancer

Status:
Unknown status
Trial end date:
2021-01-11
Target enrollment:
Participant gender:
Summary
Due to the great toxicity of chemotherapeutic drugs to both the healthy and cancerous area, the efficient targeting could be of great benefit for a patient with advanced or metastatic tumors. Colorectal cells carry somatostatin receptors which make them a promising target for antitumor therapy since this would reduce side effects and increase drug delivery efficacy to the target site.
Phase:
Phase 1
Details
Lead Sponsor:
Ahmed A. H. Abdellatif
Treatments:
Cetuximab
Somatostatin